Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6635766 | 0.77 | HDAC3 (0.50) | LMNAL3MBTL1HTTHDAC3HDAC1 | |
| SCHEMBL6635776 | 0.76 | L3MBTL1 (0.46) | LMNAL3MBTL1KDM4ECYP1A2PKM | |
| SCHEMBL22768527 | 0.75 | MMP8 (0.33) | L3MBTL1RAB9AHTT | |
| SCHEMBL1512247 | 0.75 | — | — | |
| SCHEMBL6636353 | 0.73 | HDAC1 (0.53) | HDAC3HDAC1HDAC6 | |
| SCHEMBL6639593 | 0.73 | CYP2D6 (0.39) | L3MBTL1HTTKDM4EHDAC3 | |
| SCHEMBL1346149 | 0.72 | — | — | |
| SCHEMBL23943316 | 0.72 | LMNA (0.30) | LMNAL3MBTL1HTT | |
| SCHEMBL14535559 | 0.72 | LMNA (0.34) | LMNA | |
| SCHEMBL12654606 | 0.72 | L3MBTL1 (0.32) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399405-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | Alleron therapeutics, Inc (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20080262200-A1 | Triazole Macrocycle Systems | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1420044-A2 | Rubber composition and pneumatic tire | Bridgestone Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6380288-B1 | LOW HEAT GENERATION PROPERTY, AGING REISTANCE, ALSO FOR PRODUCING VIBRATION ISOLATORS, BELTS AND HOSES AS WELL AS TIRE MATERIALS SUCH AS TIRE TREADS, UNDERTREADS, CARCASSES, SIDE WALLS AND BEADS | BRIDGESTONE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-0909788-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRES | Bridgestone Corporation (JP) | 1999-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262200-A1 | Triazole Macrocycle Systems | FLT3, VIP, NGLY1 | LMNA 4013/4885L3MBTL1 1750/4885RAB9A 4236/4885 |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | LMNA 3419/4885L3MBTL1 709/4885RAB9A 4343/4885 |
| US-20120190818-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | LMNA 4013/4885L3MBTL1 1750/4885RAB9A 4236/4885 |
| US-20120115793-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | LMNA 3419/4885L3MBTL1 709/4885RAB9A 4343/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | LMNA 2575/4885L3MBTL1 1351/4885RAB9A 4361/4885 |
| US-20120040889-A1 | PEPTIDOMIMETIC MACROCYCLES | ZC3HAV1, HAVCR2, ZC3HAV1L | LMNA 3672/4885L3MBTL1 509/4885RAB9A 4202/4885 |
| US-20120115783-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | LMNA 3419/4885L3MBTL1 709/4885RAB9A 4343/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | LMNA 2688/4885L3MBTL1 1368/4885RAB9A 3719/4885 |
| US-20120172311-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | LMNA 2575/4885L3MBTL1 1351/4885RAB9A 4361/4885 |
| US-20120178700-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | LMNA 3419/4885L3MBTL1 709/4885RAB9A 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.